Sugi Predict

Sugi Predict / Compounds / SCHEMBL46464

SCHEMBL46464

SCHEMBL46464

COC(=O)c1ccc(-c2ccc(/C=C3\SC(=S)N(Cc4ccccc4)C3=O)o2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.75
▸ MEN1 O00255 3/20 0.67
▸ ALDH1A1 P00352 3/20 0.67
▸ MAPT P10636 3/20 0.67
▸ KMT2A Q03164 3/20 0.67
▸ MCL1 Q07820 3/20 0.67
▸ RECQL P46063 2/20 0.67
▸ POLB P06746 2/20 0.67
▸ NPSR1 Q6W5P4 2/20 0.67
▸ EIF4E P06730 1/20 0.67
▸ EIF4G1 Q04637 1/20 0.67
▸ THRB P10828 1/20 0.67
▸ TDP1 Q9NUW8 1/20 0.67
▸ STAT3 P40763 1/20 0.65
▸ ENPP2 Q13822 2/20 0.64
▸ LMNA P02545 1/20 0.62
▸ ALOX12 P18054 1/20 0.62
▸ PTPN22 Q9Y2R2 2/20 0.61
▸ PKM P14618 1/20 0.61
▸ PTPN7 P35236 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6742616 1.00 SYK (0.75) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL23171552 1.00 SYK (0.75) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL4397324 0.92 SYK (0.63) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL4397326 0.92 SYK (0.63) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL4394820 0.91 EP300 (0.69) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL14025845 0.91 EP300 (0.69) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL23171421 0.91 STAT3 (0.65) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL4394822 0.91 EP300 (0.69) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL23171692 0.91 MEN1 (0.67) SYKMEN1ALDH1A1MAPTKMT2A
SCHEMBL23171599 0.91 SYK (0.64) SYKMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227443-A1 SOLID FORMS OF(Z)-4-(5-((3-BENZYL-4-OXO-2-THIOXOTHIAZOLIDIN-5-YLIDENE)METHYL)FURAN-2-YL)BENZOIC ACID ATEGRIN, INC. 2023-07-20 — — US disclosed
WO-2021061665-A1 INTEGRIN AGONIST PRODRUGS GB006, INC. (US) 2021-04-01 — — WO disclosed
EP-3243821-B1 PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 GB006 INC (US) 2020-02-26 — — EP disclosed
EP-2838614-B1 COMPOSITIONS FOR REGULATING INTEGRINS GB006 INC (US) 2019-09-11 — — EP disclosed
US-10239871-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2019-03-26 — — US disclosed
US-20160151336-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2016-06-02 — — US disclosed
US-20160151336-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2016-06-02 — — US disclosed
US-9328105-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2016-05-03 — — US disclosed
US-9328105-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2016-05-03 — — US disclosed
US-9023876-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2015-05-05 — — US disclosed
US-9023876-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2015-05-05 — — US disclosed
US-20150105435-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2015-04-16 — — US disclosed
US-20150105435-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2015-04-16 — — US disclosed
US-20120010255-A1 Compounds and Methods for Regulating Integrins ATEGRIN, INC. 2012-01-12 — — US disclosed
US-20120010255-A1 Compounds and Methods for Regulating Integrins ATEGRIN, INC. 2012-01-12 — — US disclosed
WO-2012005800-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 ADHAERE PHARAMACEUTICALS, INC. (US) 2012-01-12 — — WO disclosed
US-20040002526-A1 Phospholipase D inhibitors and uses thereof CELL THERAPEUTICS, INC. 2004-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239871-B2 Compounds and methods for regulating integrins ITGA2, ITGB2, ITGA2B SYK 476/4885MEN1 2635/4885ALDH1A1 1927/4885
US-20040002526-A1 Phospholipase D inhibitors and uses thereof PLD2, PLD1, PLA2G2D SYK 441/4885MEN1 3009/4885ALDH1A1 1070/4885
US-20120010255-A1 Compounds and Methods for Regulating Integrins ITGB8, ITGB3, ITGAM SYK 1605/4885MEN1 1586/4885ALDH1A1 473/4885
US-20230227443-A1 SOLID FORMS OF(Z)-4-(5-((3-BENZYL-4-OXO-2-THIOXOTHIAZOLIDIN-5-YLIDENE)METHYL)FURAN-2-YL)BENZOIC ACID ITGA1, ITGAL, ITGB1 SYK 339/4885MEN1 1696/4885ALDH1A1 667/4885
US-20150105435-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ITGA2, ITGB2, ITGA2B SYK 476/4885MEN1 2635/4885ALDH1A1 1927/4885
US-20160151336-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ITGA2, ITGB2, ITGA2B SYK 476/4885MEN1 2635/4885ALDH1A1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.